How should I manage a woman with resistant hypertension (blood pressure 160/90 mm Hg) who is already taking amlodipine and losartan?

Management of Resistant Hypertension on Amlodipine and Losartan

Add a thiazide-like diuretic (chlorthalidone 12.5–25 mg daily or indapamide 1.5–2.5 mg daily) as your third agent to complete the guideline-recommended foundation regimen, then reassess in 2–4 weeks before considering spironolactone as a fourth-line agent. 1, 2

Step 1: Confirm True Resistant Hypertension

Before intensifying therapy, you must exclude pseudo-resistance:

• Obtain 24-hour ambulatory blood pressure monitoring (ABPM) or home BP monitoring to rule out white-coat hypertension, which accounts for approximately 50% of apparent resistant cases. 3, 1, 2 Target confirmation is ABPM ≥130/80 mmHg or home BP ≥135/85 mmHg. 1

• Verify medication adherence rigorously through direct questioning, pill counts, or pharmacy refill records—nonadherence is responsible for roughly half of treatment resistance. 3, 1, 2

• Confirm proper BP measurement technique using an appropriately sized cuff for the patient's arm circumference and correct positioning, as improper technique yields falsely elevated readings. 3, 1, 2

Step 2: Complete the Three-Drug Foundation Regimen

Your patient is currently on only two agents (amlodipine + losartan). The cornerstone of resistant hypertension management requires three drugs from different classes at maximal tolerated doses:

• Add chlorthalidone 12.5–25 mg once daily OR indapamide 1.5–2.5 mg once daily to complete the required foundation of: (1) RAS blocker, (2) long-acting calcium channel blocker, and (3) thiazide-like diuretic. 1, 2 Thiazide-like diuretics provide markedly superior 24-hour BP control compared to hydrochlorothiazide and are significantly more effective in resistant hypertension. 1, 2

• Ensure losartan is at maximal dose (100 mg daily) and amlodipine is at maximal dose (10 mg daily) before adding a fourth agent. 1, 2 Inadequate dosing of the core three drugs is a common cause of treatment failure. 1

• If the patient has eGFR <30 mL/min/1.73m² or clinical volume overload, switch to a loop diuretic (furosemide or torsemide) instead of a thiazide-like agent, as thiazides lose efficacy at low GFR and volume overload is a frequently unrecognized cause of resistance. 1, 2

Step 3: Implement Intensive Lifestyle Modifications

These interventions can lower systolic BP by 5–15 mmHg and are essential adjuncts:

• Restrict dietary sodium to <2,400 mg/day (<100 mEq/24 hours), which typically produces 5–10 mmHg systolic reduction. 3, 1

• Encourage weight loss if BMI ≥25 kg/m²—a 10-kg reduction yields approximately 6 mmHg systolic drop. 3, 1

• Prescribe ≥150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking, stationary cycling), which produces an additional 4 mmHg systolic reduction. 3, 1

• Limit alcohol to ≤2 drinks/day for men, ≤1 drink/day for women. 3, 1

• Discontinue or minimize NSAIDs, oral contraceptives, stimulants, and certain antidepressants that directly interfere with BP control. 3, 1

Step 4: Screen for Secondary Causes

Before adding a fourth agent, evaluate for reversible causes:

• Check morning plasma aldosterone and plasma renin activity to screen for primary aldosteronism; an aldosterone/renin ratio >20–30 is suggestive even when potassium is normal. 3, 1, 2

• Screen for obstructive sleep apnea using validated questionnaires (snoring, witnessed apneas, daytime sleepiness) and refer for sleep study if positive, as OSA is highly prevalent in resistant hypertension. 3, 1, 2

• Assess baseline eGFR and check TSH to evaluate for chronic kidney disease and thyroid dysfunction. 1, 2

• Consider renal artery stenosis in younger patients (especially women with fibromuscular dysplasia), those with known atherosclerotic disease, or worsening renal function; evaluate with duplex ultrasound, MRA, or CTA. 1, 2

Step 5: Add Spironolactone as Fourth-Line Agent (If BP Remains ≥130/80 mmHg)

After 2–4 weeks on the optimized three-drug regimen, if BP remains uncontrolled:

• Add spironolactone 25 mg once daily (titrate to 50 mg after 4–6 weeks if needed) provided serum potassium is <4.5 mmol/L and eGFR >45 mL/min/1.73m². 1, 2 The PATHWAY-2 trial demonstrated that spironolactone produces an office systolic BP reduction of approximately 13–20 mmHg, making it the most effective fourth-line agent. 1, 2

• Monitor serum potassium and creatinine 5–7 days after initiating spironolactone, then every 3–6 months, as hyperkalemia is the primary safety concern, especially with concurrent RAS blockade. 1, 2

• Approximately 70% of adults with resistant hypertension meet the potassium and renal function criteria for spironolactone. 1

Alternative Fourth-Line Agents (If Spironolactone Contraindicated)

If spironolactone cannot be used due to hyperkalemia, reduced eGFR, or intolerance:

• Eplerenone 50–100 mg daily (up to 200 mg, potentially divided twice daily) causes less gynecomastia but requires higher dosing for equivalent BP reduction. 1

• Vasodilating beta-blockers (labetalol, carvedilol, or nebivolol) are the safest option for patients unable to undergo regular potassium monitoring, though they are less potent than spironolactone. 1

• Doxazosin 1–16 mg once daily may be considered, especially in men with benign prostatic hyperplasia; initiate at 1 mg at bedtime and titrate gradually to mitigate orthostatic hypotension. 1

Blood Pressure Target and Monitoring

• Target BP <130/80 mmHg for most adults with resistant hypertension; when tolerated, a more intensive systolic target of 120–129 mmHg is recommended. 1, 2

• Reassess BP response 2–4 weeks after any medication adjustment and use home BP monitoring to guide titration and improve adherence. 1, 2

Specialist Referral

• Refer to a hypertension specialist if BP remains >130/80 mmHg after optimizing the four-drug regimen (RAS blocker + CCB + thiazide-like diuretic + spironolactone) with lifestyle modifications, or if complications arise such as severe hyperkalemia, progressive renal dysfunction, or difficulty managing the regimen. 1, 2

Critical Pitfalls to Avoid

• Do not add a fourth agent before establishing the proper three-drug foundation at maximal tolerated doses—this is the most common error in resistant hypertension management. 1

• Never use hydrochlorothiazide when chlorthalidone or indapamide are available, as thiazide-like diuretics are markedly superior for resistant hypertension. 1, 2

• Do not combine an ACE inhibitor with an ARB—dual RAS blockade does not reduce cardiovascular events and increases adverse effects including hyperkalemia and renal dysfunction. 1

• Avoid extremely rapid BP reduction, as it may cause cerebral hypoperfusion, stroke, or myocardial/renal damage. 1